NCT05174585 - JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 18, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2026

Conditions

Solid Tumor

Interventions

BIOLOGICAL

JAB-BX102 (anti-CD73 monoclonal antibody)

Administered by intravenous infusion (IV)

BIOLOGICAL

pembrolizumab (anti-PD-1 monoclonal antibody)

Administered by intravenous infusion (IV)

Trial Locations (6)

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

RECRUITING

Peking University Third Hospital, Beijing

RECRUITING

Huashan Hospital, Shanghai

RECRUITING

The First Affiliated Hospital of Bengbu Medical College, Bengbu

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

NOT_YET_RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou